1-(2-pyridinylacetyl)-5-indolinamine | 474519-80-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(2-pyridinylacetyl)-5-indolinamine
• 英文别名: 1-(5-Aminoindolin-1-yl)-2-(pyridin-2-yl)ethanone；1-(5-amino-2,3-dihydroindol-1-yl)-2-pyridin-2-ylethanone
• CAS: 474519-80-7
• 化学式: C₁₅H₁₅N₃O
• 分子量: 253.304
• InChiKey: CBRQHIYVMWBYCW-UHFFFAOYSA-N

物化性质

• 沸点：
  570.6±50.0 °C(Predicted)
• 密度：
  1.285±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-pyridinylacetyl)-5-indolinamine 、 2-氯烟酸 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 生成 2-chloro-N-[1-(2-pyridinylacetyl)-2,3-dihydro-1H-indol-5-yl]nicotinamide
  参考文献：
  名称：

  [EN] AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA
  [FR] COMPOSES AMIDE

  摘要：

  公开号：

  WO2004039795A3
• 作为产物：
  描述：

  5-nitro-1-(2-pyridinylacetyl)indoline 在 钯 氢气 、 钯 、 silica gel 、 甲醇乙酸乙酯 作用下， 以 甲醇 、 四氢呋喃 为溶剂， 反应 5.0h， 以to give 1-(2-pyridinylacetyl)-5-indolinamine (2.16 g) as pale brown crystals的产率得到1-(2-pyridinylacetyl)-5-indolinamine
  参考文献：
  名称：

  Amide compounds

  摘要：

  本发明涉及公式（I）的化合物，其中X1为R1，R2和R10分别为氢原子或适当的取代基；R11和R12分别为氢原子或适当的取代基；R为不饱和的5至6元杂环单环基；A为直接键或—NH—；X2为单环芳烃，不饱和的5至6元杂环单环基或环烯基；Y为乙烯基，三亚甲基或乙烯基中选择的双价基团，其中CH2可以被NH或O替代，CH可以被N替代；Z为—（CH2）n—，—CO—（CH2）m—，—CH=CH—或—CO—NH—，其中n为1、2或3，m为1或2，或其盐。本发明的化合物抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由于Apo B循环水平升高而导致的疾病或病症的药物。

  公开号：

  US20040157866A1

文献信息

• Amide compounds
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：US20040133008A1

  公开（公告）日：2004-07-08

  A compound of the formula (I) 1 wherein R 1 is hydrogen, lower alkyl, lower alkenyl, halo(lower)alkyl, cyclo(lower)alkyl, lower alkoxy, lower alkylthio, acyl, optionally substituted aryl or NR 3 R 4 ; R 2 is hydrogen; or aryl or heteroaryl, each of which may be substituted; X is direct bond or bivalent residue derived from piperazine; Y is -(A 1 ) n -(A 2 ) m -, wherein n and m are independently 0 or 1); 2 is bivalent residue derived from arene or heteroarene; and 3 is bivalent residue derived from arene or heteroarene, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

  化合物的式子为（I）1，其中R1为氢、低级烷基、低级烯基、卤素（低）烷基、环（低）烷基、低级烷氧基、低级烷硫基、酰基、可选取代的芳基或NR3R4；R2为氢；或芳基或杂环芳基，每个可以被取代；X为直接键或由哌嗪衍生的二价残基；Y为-(A1)n-(A2)m-，其中n和m独立地为0或1）；2为由芳烃或杂芳烃衍生的二价残基；3为由芳烃或杂芳烃衍生的二价残基，或其盐。本发明的化合物及其盐抑制载脂蛋白B（Apo B）的分泌，并可用作预防和治疗由高循环Apo B水平引起的疾病或状况的药物。
• BIARYLCARBOXAMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1383760A1

  公开（公告）日：2004-01-28
• HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1472226A1

  公开（公告）日：2004-11-03
• [EN] AMIDE COMPOUNDS<br/>[FR] COMPOSES BIARYLCARBOXAMIDE COMME INHIBITEURS D'APOLIPOPROTEINE B
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2002090347A1

  公开（公告）日：2002-11-14

  The present invention relates to compounds of the formula (I) wherein X1 is wherein R?1, R2 and R10¿ are independently hydrogen or a suitable substituent; R?11 and R12¿ are independently hydrogen or a suitable substituent; R is unsaturated 5 to 6-membered heteromonocyclic group; A is direct bond or -NH-; X2 is monocyclic arylene, unsaturated 5 to 6-membered heteromonocyclic group or cycloalkenylene; Y is bivalent group selected from ethylene, trimethylene and vinylene, wherein CH2 is optionally replaced by NH or O, and CH is optionally replaced by N; and Z is -(CH¿2?)n-, -CO-(CH2)m-, -CH=CH- or -CO-NH-, wherein n is 1, 2 or 3 and m is 1 or 2, or a salt thereof. The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.
• [EN] HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS<br/>[FR] COMPOSES D'AMIDE HETEROCYCLIQUES EN TANT QU'INHIBITEURS DE L'APOLIPOPROTEINE B
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2003045921A1

  公开（公告）日：2003-06-05

  The present invention relates to a compound of the formula (I) wherein R1 is optionally substituted aryl; R2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted lower cycloalkyl, optionally substituted aryloxy, optionally substituted arylsulfonyl, vinyl, carbamoyl, protected carboxy or protected amino; ring A is bivalent residue derived from optionally substituted aryl or optionally substituted heteroaryl; X is bivalent residue derived from the group consisting of cycloalkene, naphthalene, unsaturated 5 or 6-membered heteromonocyclic group, each of which is optionally substituted, and substituted benzene; Y is -(A1)m1-(A2)m2-; and Z is direct bond or piperazine, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.